What is triple-negative breast cancer?
According to the U.S. National Cancer Institute (NCI), triple-negative breast cancer (TNBC) is a type of breast cancer in which the tumor cells do not have estrogen receptors (ER-negative), progesterone receptors (PR-negative), or large amounts of HER2/neu protein (HER2-negative). Because those receptors and that protein are missing, the hormone therapy and HER2-targeted drugs used for other breast cancers have no target to act on and are not used to treat TNBC. NCI notes that it is often treated with chemotherapy, and that for some people the immunotherapy drug pembrolizumab may be given together with chemotherapy. This is general information, not personal medical advice; discuss your situation with your own care team.
Last updated:
Verify at
NCI Dictionary of Cancer Terms — triple-negative breast cancer (opens in a new tab) — National Cancer Institute (NCI)
Triple-negative Breast Cancer — Treatment (opens in a new tab) — National Cancer Institute (NCI)
Related questions
- What does HER2-positive mean in breast cancer?
- What does PD-L1 mean in cancer immunotherapy?
- What is a BRCA gene mutation and which cancers is it linked to?
- What is an EGFR mutation in lung cancer, and why does it matter for treatment?
- What is DCIS (ductal carcinoma in situ)?
- What is the difference between small cell and non-small cell lung cancer?